INIS
patients
100%
cancer
84%
pancreas
56%
metastases
25%
adenocarcinomas
23%
chemotherapy
21%
tumors
21%
surgery
18%
populations
14%
therapy
12%
diseases
12%
netherlands
12%
data
10%
combined therapy
10%
comparative evaluations
9%
toxicity
7%
doses
6%
quality of life
6%
solids
6%
risks
6%
esophagus
6%
radiotherapy
5%
Keyphrases
Pancreatic Cancer
21%
Overall Survival
17%
Pancreatic Ductal Adenocarcinoma
13%
Chemotherapy
12%
Netherlands
11%
National Cohort Study
8%
Borderline Resectable Pancreatic Cancer
7%
Resection
7%
Median Overall Survival
7%
FOLFIRINOX
7%
Cancer Patients
7%
Resectable Pancreatic Cancer
7%
Gemcitabine
6%
Dutch
5%
Population-based Study
5%
Adjuvant Chemotherapy
5%
Treatment Survival
5%
Periampullary Cancer
5%
Cancer Registry
5%
Subnational Analysis
5%
Advanced Solid Tumors
5%
Pancreaticoduodenectomy
5%
Medicine and Dentistry
Pancreas Cancer
36%
Overall Survival
22%
Pancreas Adenocarcinoma
17%
Malignant Neoplasm
12%
Chemoradiotherapy
11%
Neoplasm
9%
Gemcitabine
8%
Cohort Analysis
8%
Systemic Therapy
8%
Cancer Therapy
6%
Randomized Controlled Trial
5%
Cancer Registry
5%
Adjuvant Chemotherapy
5%
Pancreaticoduodenectomy
5%
Diseases
5%